<DOC>
	<DOCNO>NCT02825550</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Radiopaque Microsphere ( T-ACE Beads ) interventional therapy liver cancer</brief_summary>
	<brief_title>Taiwan ACE Beads Hepatoma Embolization Therapy</brief_title>
	<detailed_description>The study evaluate safety tolerability Taiwan ACE Beads use chemoembolization treatment unresectable hepatocellular carcinoma . The investigator study overall response rate lesion Taiwan ACE Beads . In study , procedure similar conventional TACE ( transcatheter arterial chemoembolization ) . At target vessel , radiologist inject lipiodol doxorubicin first , Taiwan ACE Beads instead Gelfoam PVA ( polyvinyl alcohol ) . The end point injection also similar conventional TACE . Determine complication rate , progression free survival ( PFS ) overall survival ( OS ) follow Taiwan ACE Beads embolization .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients must meet follow inclusion criterion order enter study : A . Both gender patient age 18 older . B . Patients diagnose liver cancer ( MUST meet least ONE follow criterion : ) 1 . Diagnosed via tumor biopsy Pathologists , confirm onservice physician . 2 . High risk patient ( Viral hepatitis B C cirrhotics ) typical liver cancer image appear two radiographic examination ( Ultrasound , MRI , CT scan Angiography ) . 3 . High risk patient ( Viral hepatitis B C cirrhotics ) evidence enlarge image liver cancer via two followup record . C. In intermediate stage BCLC staging , tumor size 3 6 centimeter , liver function ChildPugh class &lt; 9 , either difficult accept operation reluctant accept operation . D. Disease treat transarterial chemoembolization , evaluate Ultrasound , Magnetic resonance imaging ( MRI ) , compute tomography ( CT ) . E. Performance status ECOG 2 less . Patient life expectancy least 3 month . If patient meet follow criterion may enter study : A. major branch portal vein invade already ; extrahepatic metastasis malignant tumor . B. Evidences decompensation : Total Bilirubin &gt; 2 , PT prolong &gt; 3 second , AST &gt; 500U/L , ALT &gt; 500U/L , ChildPugh classâ‰§9 , refractory ascites , active bleeding , hepatic encephalopathy , severe infection . C. Tumor size ( diameter ) large 6 centimeter small 3 centimeter . D. Cr &gt; 2.0 mg/dL eGFR &lt; 50 % . E. Allergic iodine injection . F. Other main organ failure ( Heart , Lung , Kidney ) G. WBC &lt; 3000 , ANC &lt; 1500 . H. Performance status ECOG 3 . I . Unable followup ultrasound CT scan . J . Unwilling sign write informed consent form . K. Pregnant woman breath feed woman . L. Patients whose blood vessel difficult Taiwan ACE Beads procedure . M. Prominent AV shunt . N. Severe atherosclerosis . O. Vasospasm possible major vascular injury . P. Arteriovenous shunt patient , diameter large size microsphere available . Q . Collateral vascular exists may endanger nontargeted area arterial chemoembolization . R. Contraindications doxorubicin . S. Number tumor 3 locate different lobe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatoma</keyword>
	<keyword>Transcatheter Arterial chemo-embolization</keyword>
	<keyword>microsphere</keyword>
</DOC>